Skip to Content
  • Title
    CEO
  • Affiliation
    Mylan
  • Age
    46

Bresch has overseen a lot of drama at generic-drug maker Mylan in her nearly four years as CEO. After acquiring part of Abbott Laboratories earlier this year, Bresch moved the $7.7 billion Mylan to the Netherlands in a controversial “tax inversion” play, then thwarted a plan from Israel-based Teva to buy Mylan for $40 billion. Now Bresch is trying her own hostile takeover of Ireland-based Perrigo.

Read more about Heather Bresch in “Why Wall Street loves to hate Mylan’s CEO.”

Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Personal Information

Previous Rank31
Newcomer?
no

Company Financials

2014 Revenues
7,720
2014 Profits
929
Market Value (as of 9/1/15)
23,737